GlassScriptPhysician profile
Satish K Solanki
NPI 1700821063
$19,432.36
in general payments reported to CMS, 2019-2025
52 companies · $3,568 in 2025
The $3,568 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,046 · 2020: $1,473 · 2021: $2,642 · 2022: $2,890 · 2023: $3,350 · 2024: $3,463 · 2025: $3,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,039.70 |
| Education | $341.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,883.05 | 2019-2025 | Tavneos, Enbrel, Evenity |
| Abbvie INC. | $3,296.77 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $2,623.22 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $1,250.29 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,119.92 | 2019-2025 | |
| Ucb, INC. | $999.31 | 2019-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $637.64 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $634.46 | 2019-2025 | Orencia |
| Radius Health, INC. | $616.90 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.43 | 2019-2025 | Cyltezo, Ofev |
| Lilly USA, LLC | $407.96 | 2019-2025 | Taltz, Zepbound |
| Actelion Pharmaceuticals US, INC. | $333.86 | 2020-2025 | Opsumit, Uptravi, Opsynvi |
| Organon LLC | $321.80 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Horizon Therapeutics Plc | $295.79 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $253.78 | 2021-2025 | Benlysta |
Show all 51 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satish Solanki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.